Skip to main content
Top
Published in: Clinical Rheumatology 5/2010

01-05-2010 | Original Article

The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis

Published in: Clinical Rheumatology | Issue 5/2010

Login to get access

Abstract

Vascular endothelial growth factor (VEGF) is known to be involved in the pathogenesis of rheumatoid arthritis (RA). In order to elucidate the association between VEGF levels and RA disease activity, VEGF concentrations were measured in RA patients at different phases and severity levels. Thirty-eight healthy subjects and 40 patients with RA were prospectively included in the study. Subjects were further categorized into four subgroups (high, moderate, low, or remission) using the disease activity score-28 (DAS28) scoring system. VEGF levels were significantly higher in patients than controls (p < 0.001). VEGF levels differed significantly in controls, early and late-phase RA patients (p = 0.002). A significant difference was found between controls and patients with high RA disease activity scores (p < 0.0001). VEGF levels were not correlated with age (r = −0.016; p = 0.921) or sex (r = 0.209; p = 0.921). VEGF values were correlated with erythrocyte sedimentation rate (r = 0.445; p = 0.004), but was not correlated with serum rheumatoid factor levels (r = −0.130; p = 0.424) in the patient group. In conclusion, higher VEGF levels are associated with late phase and high disease activity in RA, independent of age and sex.
Literature
1.
go back to reference Koch AE, Harlow LA et al (1994) Vascular endothelial growth factor A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149–4156PubMed Koch AE, Harlow LA et al (1994) Vascular endothelial growth factor A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149–4156PubMed
2.
go back to reference Fava RA, Olsen NJ et al (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346CrossRefPubMed Fava RA, Olsen NJ et al (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346CrossRefPubMed
3.
go back to reference Kikuchi K, Kubo M et al (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049–1051CrossRefPubMed Kikuchi K, Kubo M et al (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049–1051CrossRefPubMed
4.
go back to reference Harada M, Mitsuyama K et al (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumalol 27:377–380CrossRef Harada M, Mitsuyama K et al (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumalol 27:377–380CrossRef
5.
go back to reference Paleolog EM (2009) The vasculature in rheumatoid arthritis: cause or consequence. Int J Exp Pathol 90(3):249–261PubMed Paleolog EM (2009) The vasculature in rheumatoid arthritis: cause or consequence. Int J Exp Pathol 90(3):249–261PubMed
6.
go back to reference Yoo SA, Kwok SK, Kim WU (2008) Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm Epub 2008:129873 Yoo SA, Kwok SK, Kim WU (2008) Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm Epub 2008:129873
7.
go back to reference Sone H, Sakauchi M et al (2001) Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 69:1861–1869CrossRefPubMed Sone H, Sakauchi M et al (2001) Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 69:1861–1869CrossRefPubMed
8.
go back to reference Ballara S, Taylor PC et al (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44:2055–2064CrossRefPubMed Ballara S, Taylor PC et al (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44:2055–2064CrossRefPubMed
9.
go back to reference Lee SS, Joo YS et al (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19:321–324PubMed Lee SS, Joo YS et al (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19:321–324PubMed
10.
go back to reference Latour F, Zabraniecki L et al (2001) Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological, and pathological study in 12 patients monitored for 10 years. Joint Bone Spine 68:493–498CrossRefPubMed Latour F, Zabraniecki L et al (2001) Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological, and pathological study in 12 patients monitored for 10 years. Joint Bone Spine 68:493–498CrossRefPubMed
11.
go back to reference Klimiuk PA, Sierakowski S et al (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMed Klimiuk PA, Sierakowski S et al (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMed
12.
go back to reference Drouart M, Saas P et al (2003) High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132:158–162CrossRefPubMed Drouart M, Saas P et al (2003) High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132:158–162CrossRefPubMed
13.
go back to reference Strunk J, Heinemann E, Neeck G, Schmidt KL, Lange U (2004) A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor. Rheumatology (Oxford) 43:1480–1483CrossRef Strunk J, Heinemann E, Neeck G, Schmidt KL, Lange U (2004) A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor. Rheumatology (Oxford) 43:1480–1483CrossRef
14.
go back to reference Ardicoglu O, Boz K et al (2004) Levels of vascular endothelial growth factor in patients with rheumatoid arthritis. The Pain Clinic 16:187–191CrossRef Ardicoglu O, Boz K et al (2004) Levels of vascular endothelial growth factor in patients with rheumatoid arthritis. The Pain Clinic 16:187–191CrossRef
15.
go back to reference Pinheiro GR, Andrade CA et al (2001) Serum vascular endothelial growth factor in late rheumatoid arthritis. Clin Exp Rheumatol 19:721–723PubMed Pinheiro GR, Andrade CA et al (2001) Serum vascular endothelial growth factor in late rheumatoid arthritis. Clin Exp Rheumatol 19:721–723PubMed
16.
go back to reference Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M (2005) A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 25:314–319CrossRefPubMed Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M (2005) A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 25:314–319CrossRefPubMed
17.
go back to reference Clavel G, Bessis N et al (2007) Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 124:158–164CrossRefPubMed Clavel G, Bessis N et al (2007) Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 124:158–164CrossRefPubMed
18.
go back to reference Choi ST, Kim JH, Seok JY, Park YB, Lee SK (2009) Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 28(3):333–337CrossRefPubMed Choi ST, Kim JH, Seok JY, Park YB, Lee SK (2009) Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 28(3):333–337CrossRefPubMed
19.
go back to reference Taylor PC (2005) Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology(Oxford) 44(6):721–728CrossRef Taylor PC (2005) Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology(Oxford) 44(6):721–728CrossRef
20.
go back to reference Firestein GS (1999) Starving the synovium:angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103:3–4CrossRefPubMed Firestein GS (1999) Starving the synovium:angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103:3–4CrossRefPubMed
21.
go back to reference Smolen JS, Breedveld FC et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2):244–257CrossRefPubMed Smolen JS, Breedveld FC et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2):244–257CrossRefPubMed
22.
go back to reference Hormbrey E, Gillespie P et al (2002) A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood. Is the current literature meaningful. Clin Exp Metastasis 19(8):651–663CrossRefPubMed Hormbrey E, Gillespie P et al (2002) A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood. Is the current literature meaningful. Clin Exp Metastasis 19(8):651–663CrossRefPubMed
23.
go back to reference Costa C, Incio J, Soares R (2007) Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10(3):149–166CrossRefPubMed Costa C, Incio J, Soares R (2007) Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10(3):149–166CrossRefPubMed
24.
go back to reference Paleolog EM, Young S et al (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41(7):1258–1265CrossRefPubMed Paleolog EM, Young S et al (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41(7):1258–1265CrossRefPubMed
25.
go back to reference Nagashima M, Wauke K et al (2000) Effects of combination of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 39:1255–1262CrossRef Nagashima M, Wauke K et al (2000) Effects of combination of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 39:1255–1262CrossRef
26.
go back to reference Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis—a new target for future therapy. Vascul Pharmacol 44:265–274CrossRefPubMed Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis—a new target for future therapy. Vascul Pharmacol 44:265–274CrossRefPubMed
27.
go back to reference Kurosaka D, Hirai K et al (2009) Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis. Mod Rheumatol 19(2):187–191CrossRefPubMed Kurosaka D, Hirai K et al (2009) Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis. Mod Rheumatol 19(2):187–191CrossRefPubMed
Metadata
Title
The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis
Publication date
01-05-2010
Published in
Clinical Rheumatology / Issue 5/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1343-4

Other articles of this Issue 5/2010

Clinical Rheumatology 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine